ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Development and validation of a pyroptosis-related genes signature for risk stratification in gliomas

Sun, Penggang; Wang, Xinyu; Zhong, Junzhe; Yu, Daohan; Xuan, Hanwen; Xu, Tianye; Song, Dan; Yang, Changxiao; Wang, Pandeng; Liu, Yuxiang; Meng, Xiangqi*; Cai, Jinquan*哈尔滨医科大学
Frontiers in Genetics2023-2-13DOI: 10.3389/fgene.2023.1087563
3被引12阅读
引用收藏
分享

摘要

Background: Glioma is a highly heterogeneous disease, causing the prognostic prediction a challenge. Pyroptosis, a programmed cell death mediated by gasdermin (GSDM), is characterized by cell swelling and the release of inflammatory factors. Pyroptosis occurs in several types of tumor cells, including gliomas. However, the value of pyroptosis-related genes (PRGs) in the prognosis of glioma remains to be further clarified.Methods: In this study, mRNA expression profiles and clinical data of glioma patients were acquired from TCGA and CGGA databases, and one hundred and eighteen PRGs were obtained from the Molecular Signatures Database and GeneCards. Then, consensus clustering analysis was performed to cluster glioma patients. The least absolute shrinkage and selection operator (LASSO) Cox regression model was used to establish a polygenic signature. Functional verification of the pyroptosis-related gene GSDMD was achieved by gene knockdown and western blotting. Moreover, the immune infiltration status between two different risk groups were analyzed through the "gsva " R package.Results: Our results demonstrated that the majority of PRGs (82.2%) were differentially expressed between lower-grade gliomas (LGG) and glioblastoma (GBM) in the TCGA cohort. In univariate Cox regression analysis, eighty-three PRGs were shown to be associated with overall survival (OS). A five-gene signature was constructed to divide patients into two risk groups. Compared with patients in the low-risk group, patients in the high-risk group had obviously shorter OS (p < 0.001). Also, we found that the high-risk group showed a higher infiltrating score of immune cells and immune-related functions. Risk score was an independent predictor of OS (HR > 1, p < 0.001). Furthermore, knockdown of GSDMD decreased the expression of IL-1 beta and cleaved caspase-1.Conclusion: Our study constructed a new PRGs signature, which can be used to predict the prognosis of glioma patients. Targeting pyroptosis might serve as a potential therapeutic strategy for glioma.

学科与关键词

关键词
gliomapyroptosisgene signatureoverall survivalimmune status
相关
加载中…
  • Construction and Verification of a Novel Pyroptosis-Related lncRNA Signature Associated with Immune Landscape in Gliomas
    Feng, Xiaoqiang; Chen, Yuehua; Liu, Xuanyu; Zhong, Zhihui; Liu, Yanjun*Journal of Oncology, 2022, 2022: 7043431.
  • Optimization of cancer immunotherapy through pyroptosis: A pyroptosis-related signature predicts survival benefit and potential synergy for immunotherapy in glioma
    Zeng, Yu; Cai, Yonghua; Chai, Peng; Mao, Yangqi; Chen, Yanwen; Wang, Li; Zeng, Kunlin; Zhan, Ziling; Xie, Yuxin; Li, Cuiying; Zhan, Hongchao; Zhao, Liqian; Chen, Xiaoxia; Zhu, Xiaoxia; Liu, Yu; Chen, Ming*; Song, Ye*; Zhou, Aidong*Frontiers in Immunology, 2022, 13: 961933.被引 4
  • A Pyroptosis-Related Gene Signature for Predicting Survival in Glioblastoma.
    Li, Xin-Yu; Zhang, Lu-Yu; Li, Xue-Yuan; Yang, Xi-Tao; Su, Li-XinFrontiers in Oncology, 2021, 11: 697198.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Genetics
发表日期
2023-02-13
卷期
第 14 卷
页码
1087563
DOI
10.3389/fgene.2023.1087563
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82073298, 82003022]; Heilongjiang Provincial Key RD Project [GA21C002]; Central Government Supporting Local University Reform and Development Fund for Excellent Youth Talents [0202-300011190006]; China Postdoctoral Science Foundation [2022T150173, 2020T130157, 2019M660074]; Heilongjiang Postdoctoral Science Foundation [LBH-TZ2113, LBH-Z19029]; Research Project of the Health and Family Planning Commission of Heilongjiang Province [2019-102]

作者

  • S

    Sun, Penggang (第一作者)

    2 · harbin med univ

  • W

    Wang, Xinyu

    2 · harbin med univ

查看全部 12 位作者收起作者
  • Z

    Zhong, Junzhe

    2 · harbin med univ

  • Y

    Yu, Daohan

    2 · harbin med univ

  • X

    Xuan, Hanwen

    2 · harbin med univ

  • X

    Xu, Tianye

    2 · harbin med univ

  • S

    Song, Dan

    2 · harbin med univ

  • Y

    Yang, Changxiao

    2 · harbin med univ

  • W

    Wang, Pandeng

    2 · harbin med univ

  • L

    Liu, Yuxiang

    2 · harbin med univ

  • M

    Meng, Xiangqi (通讯)

    2 · harbin med univ

  • C

    Cai, Jinquan (通讯)

    2 · harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417